BioAffinity.jpg
bioAffinity Technologies Announces Formation of Scientific and Medical Advisory Board; M. Patricia Rivera, MD, Joins Board as Chair
12. März 2019 11:00 ET | bioAffinity Technologies, Inc.
SAN ANTONIO, March 12, 2019 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, today announced the formation of a Scientific and Medical Advisory (SMA) Board to provide...
BioAffinity.jpg
bioAffinity Technologies Selected as Finalist for Cancer Innovation Award
06. März 2019 11:00 ET | bioAffinity Technologies, Inc.
SAN ANTONIO, March 06, 2019 (GLOBE NEWSWIRE) -- Healthcare innovators Lyfebulb and Helsinn selected bioAffinity Technologies, a privately held biotech company developing diagnostics and therapeutics...
BioAffinity.jpg
South Texas Veterans Health Care System Joins Test Validation Trial of bioAffinity’s CyPath® Lung
23. Oktober 2018 11:00 ET | bioAffinity Technologies, Inc.
SAN ANTONIO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, today announced that the South Texas Veterans Health Care System (STVHCS), which is...
BioAffinity.jpg
Mount Sinai Joins Test Validation Trial of bioAffinity’s CyPath® Lung
18. September 2018 14:00 ET | bioAffinity Technologies, Inc.
SAN ANTONIO, Sept. 18, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, today announced that the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY,...
BioAffinity.jpg
bioAffinity Technologies Welcomes Mohsin Y. Meghji to Board of Directors
31. Juli 2018 11:00 ET | bioAffinity Technologies, Inc.
SAN ANTONIO, July 31, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biomedical company advancing breakthrough cancer diagnostics and therapeutics, is pleased to welcome Mohsin...
BioAffinity.jpg
bioAffinity Technologies Opens Test Validation Trial of CyPath® Lung
17. Juli 2018 14:40 ET | bioAffinity Technologies, Inc.
SAN ANTONIO, July 17, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held cancer diagnostics company, today announced it has commenced its test validation trial for CyPath® Lung, an...
BioAffinity.jpg
bioAffinity Technologies to Present at Biotech Showcase™ Annual Conference
05. Januar 2018 09:00 ET | bioAffinity Technologies, Inc.
SAN ANTONIO, Texas, Jan. 05, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held cancer diagnostics company, today announced that it will present its proprietary technology to detect...
BioAffinity.jpg
bioAffinity Technologies Welcomes New Board Members
29. November 2017 11:00 ET | bioAffinity Technologies, Inc.
SAN ANTONIO, Nov. 29, 2017 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held cancer diagnostics and therapeutics company, today announced the appointments of Stephen Squinto, Ph.D., and...
BioAffinity.jpg
bioAffinity Technologies Announces $4 Million Series A Funding
19. Juli 2017 15:00 ET | bioAffinity Technologies, Inc.
SAN ANTONIO, July 19, 2017 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held company advancing early-stage cancer diagnostics and precision therapeutics, announced today that it raised...
BioAffinity.jpg
City of San Antonio Invests in bioAffinity Technologies
09. März 2017 19:02 ET | bioAffinity Technologies, Inc.
SAN ANTONIO, March 09, 2017 (GLOBE NEWSWIRE) -- The San Antonio City Council today authorized the San Antonio Economic Development Corporation (SAEDC) to invest in locally based bioAffinity...